60 Degrees Pharmaceuticals, Inc.

Name: 60 Degrees Pharmaceuticals, Inc. standardized financial statements, quarterly
Creator: Listed

SXTPNasdaqCIK 1946563HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$207.9k, Q2 FY2026

Operating income−$2.3m, Q2 FY2026

Net income−$2.3m, Q2 FY2026

60 Degrees Pharmaceuticals, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$k	51.2	126	106	125	135	242	164	101	438	303	162	208
Cost of revenue	$k	71.2	146	65.4	89.6	112	118	73.3	50.1	538	121	85.7	151
Gross profit	$k	(20.0)	(20.6)	40.2	35.4	23.6	124	90.3	50.9	(100)	183	76.4	56.8
Research and development	$k	264	100	337	3,095	940	614	371	232	810	639	281	599
Operating income	$k	(1,522)	(1,894)	(1,342)	(4,189)	(2,119)	(2,065)	(1,911)	(1,606)	(2,326)	(1,917)	(2,095)	(2,271)
Interest expense	$k	40.1	5.4	1.4	3.6	1.5	1.4	1.8	1.2	1.7	3.1	1.4	1.4
Income tax	$k	0.1	0.1	0.1	0.4	0.3	(0.8)	0.1	1.5	0.3	(1.8)	not reported	not reported
Net income	$k	4,183	(2,012)	430	(4,173)	(2,160)	(2,045)	(1,877)	(1,734)	(2,316)	(1,439)	(2,089)	(2,265)
Diluted EPS	$ per share	9.13	not reported	1.83	(21.12)	(2.92)	not reported	(6.25)	(5.01)	(0.66)	not reported	(1.28)	(0.90)
Basic EPS	$ per share	9.13	not reported	1.83	(21.12)	(4.65)	not reported	(6.25)	(5.01)	(0.66)	not reported	(1.28)	(0.90)

Balance sheet

Cash and equivalents$1.0m, Q2 FY2026

Long-term debt$150.0k, Q2 FY2026

Shareholders' equity$2.6m, Q2 FY2026

60 Degrees Pharmaceuticals, Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$k	2,219	2,142	2,895	1,577	3,301	1,659	3,452	1,967	4,116	1,510	3,338	1,023
Current assets	$k	8,895	7,243	7,906	3,763	6,891	5,386	5,650	3,844	6,309	4,895	6,260	3,731
Total assets	$k	9,150	7,784	8,379	4,327	7,421	5,759	5,978	4,182	6,689	5,366	6,763	4,283
Current liabilities	$k	2,481	2,835	1,104	1,219	1,310	1,657	1,802	1,691	2,197	1,843	1,876	1,605
Total liabilities	$k	2,634	2,986	1,254	1,368	1,458	1,804	1,949	1,836	2,342	1,987	2,019	1,754
Long-term debt	$k	150	150	150	150	150	147	150	150	150	144	150	150
Current portion of debt	$k	not reported	8.8	8.8	8.8	8.8	8.8	8.8	8.8	8.8	8.8	8.8	2.0
Short-term borrowings	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Shareholders' equity	$k	6,516	4,870	7,200	3,035	6,040	4,036	4,110	2,428	4,430	3,463	4,829	2,614

Cash flow

Operating cash flow−$2.2m, Q2 FY2026

Capital expenditure$0, Q2 FY2026

60 Degrees Pharmaceuticals, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$k	(3,753)	(63.7)	(1,140)	(1,188)	(1,681)	(1,638)	(1,597)	(1,450)	(2,109)	(1,692)	(2,742)	(2,232)
Capital expenditure	$k	not reported	55.8	not reported	not reported	13.8	0.0	2.7	47.3	10.0	79.9	30.0	0.0

Diluted shares (weighted)2.65m, Q2 FY2026

60 Degrees Pharmaceuticals, Inc., shares, quarterly
Line item	Unit	period not labelled2022-09-30	period not labelled2023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	k shares	2,386	2,304	198	448	169	203	2,153	321	368	3,675	1,726	2,654

Shares outstanding: 3.52m at Aug 14, 2026, from the cover of the 10-Q filed Aug 14, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. Listed shows no prices and gives no investment advice.